Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Danaher Corporation    DHR

DANAHER CORPORATION

(DHR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Danaher : Announces Redemption of Senior Notes

10/07/2020 | 11:23am EST

WASHINGTON - Danaher Corporation (NYSE: DHR) ('Danaher') announced today that it will redeem all of the EUR800,000,000 aggregate principal amount of 1.700% Senior Notes due 2022 (NYSE: DHR /22) issued by DH Europe Finance S.A R.L. and guaranteed by Danaher (the 'Notes'), at a redemption price equal to the outstanding principal amount and a make-whole premium as specified in the indenture governing the Notes, plus accrued and unpaid interest.

The redemption date for the Notes will be November 5, 2020. Danaher intends to fund the redemption using a portion of the proceeds of its recent offering of senior notes.

ABOUT DANAHER

Danaher is a global science and technology innovator committed to helping its customers solve complex challenges and improving quality of life around the world. Its family of world class brands has leadership positions in the demanding and attractive health care, environmental and applied end-markets. With more than 20 operating companies, Danaher's globally diverse team of more than 67,000 associates is united by a common culture and operating system, the Danaher Business System, and its Shared Purpose, Helping Realize Life's Potential.

Contact:

Matthew E. Gugino

Tel: (202) 828-0850

(C) 2020 Electronic News Publishing, source ENP Newswire

All news about DANAHER CORPORATION
09:56aDANAHER : to Present at Evercore ISI HealthCONx Conference
AQ
11/24DANAHER : To Present At Evercore ISI HealthCONx Conference
PR
11/23DANAHER : Beckman Coulter launches its semi-quantitative SARS-CoV-2 IgG II antib..
PR
11/17DANAHER : to Present at Wolfe Research Healthcare Conference
AQ
11/16DANAHER : To Present At Wolfe Research Healthcare Conference
PR
11/11DANAHER : Releases 2020 Sustainability Report
AQ
11/10DANAHER : Releases 2020 Sustainability Report
PR
11/10DANAHER : Beckman Coulter launches its SARS-CoV-2 IgM antibody test in countries..
PR
10/27DANAHER : Cytiva strengthens support to diagnostics industry with new labs, serv..
AQ
10/23DANAHER : Reports Third Quarter 2020 Results
AQ
More news
Financials (USD)
Sales 2020 21 954 M - -
Net income 2020 3 384 M - -
Net Debt 2020 15 370 M - -
P/E ratio 2020 46,5x
Yield 2020 0,33%
Capitalization 155 B 155 B -
EV / Sales 2020 7,76x
EV / Sales 2021 6,65x
Nbr of Employees 60 000
Free-Float 74,1%
Chart DANAHER CORPORATION
Duration : Period :
Danaher Corporation Technical Analysis Chart | DHR | US2358511028 | MarketScreener
Technical analysis trends DANAHER CORPORATION
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 21
Average target price 249,50 $
Last Close Price 217,22 $
Spread / Highest target 28,9%
Spread / Average Target 14,9%
Spread / Lowest Target -36,5%
EPS Revisions
Managers
NameTitle
Rainer M. Blair President, Chief Executive Officer & Director
Steven M. Rales Chairman
Matthew R. McGrew Chief Financial Officer & Executive Vice President
Alan G. Spoon Independent Director
Walter G. Lohr Independent Director
Sector and Competitors